Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ZYUS Life Sciences Corp ZLSCF


Primary Symbol: V.ZYUS

Healthcare Biotechnology
ZYUS Life Sciences Corporation is a Canada-based life sciences company. It develops and commercializes novel cannabinoid-based pharmaceutical drug candidates for pain management. Its lead research program is focused on developing a highly purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its pre-and non-clinical studies provide the... see more

Recent & Breaking News (TSXV:ZYUS)

    ZYUS Life Sciences Corporation Announces Closing of Unsecured Loan and Amendment of Existing Shareholder Promissory Note

    Business Wire 1 day ago

    ZYUS Life Sciences Corporation Announces Unsecured Loan

    Business Wire November 4, 2024

    ZYUS Life Sciences Corporation Announces Closing of Unsecured Loan

    Business Wire September 27, 2024

    ZYUS Life Sciences Announces Closing of Private Placement

    Business Wire August 26, 2024

    ZYUS Life Sciences Receives No Objection Letter from Health Canada for Proof-of-Concept Trial

    Business Wire July 30, 2024

    ZYUS Life Sciences Receives Cannabis Drug License from Health Canada

    Business Wire June 4, 2024

    ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9

    Business Wire May 7, 2024

    ZYUS Announces Completion of Its Annual Filings

    Business Wire May 7, 2024

    ZYUS Announces Anticipated Delay in Its Annual Filings

    Business Wire April 29, 2024

    ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management

    Business Wire April 23, 2024

    ZYUS Strengthens Expertise of Clinical Advisory Committee with the Appointment of Dr. Hance Clarke

    Business Wire February 1, 2024

    ZYUS Strengthens Leadership Team with Appointment of Vice President of Clinical Research

    Business Wire January 9, 2024

    ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin® Softgel Capsules for Advanced Cancer Pain Management

    Business Wire December 5, 2023

    ZYUS Life Sciences Corporation Reports Q3 2023 Results

    Business Wire November 29, 2023

    ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels

    Business Wire November 21, 2023

    ZYUS Life Sciences Corporation Announces New Director of Investor Relations and Capital Markets

    Business Wire October 24, 2023

    ZYUS Life Sciences Corporation Obtains Health Canada Security Clearance for New Board Member Wayne Brownlee

    Business Wire August 31, 2023

    ZYUS Life Sciences Corp. Closes the Market

    Canada NewsWire July 19, 2023

    ZYUS Life Sciences Strengthens Board of Directors with the Appointment of Wayne Brownlee

    Business Wire June 29, 2023